View Future GrowthVext Science 過去の業績過去 基準チェック /06Vext Scienceの収益は年間平均-63.5%の割合で減少していますが、 Pharmaceuticals業界の収益は年間 増加しています。収益は年間9.7% 7.1%割合で 増加しています。主要情報-63.53%収益成長率-60.97%EPS成長率Pharmaceuticals 業界の成長5.95%収益成長率7.09%株主資本利益率-28.54%ネット・マージン-29.93%前回の決算情報31 Mar 2026最近の業績更新お知らせ • May 15Vext Science, Inc. to Report Q1, 2026 Results on May 21, 2026Vext Science, Inc. announced that they will report Q1, 2026 results Pre-Market on May 21, 2026お知らせ • Mar 31Vext Science, Inc. to Report Q4, 2025 Results on Apr 23, 2026Vext Science, Inc. announced that they will report Q4, 2025 results at 9:30 AM, US Eastern Standard Time on Apr 23, 2026お知らせ • Nov 11Vext Science, Inc. to Report Q3, 2025 Results on Nov 20, 2025Vext Science, Inc. announced that they will report Q3, 2025 results Pre-Market on Nov 20, 2025お知らせ • Aug 11Vext Science, Inc. to Report Q2, 2025 Results on Aug 20, 2025Vext Science, Inc. announced that they will report Q2, 2025 results Pre-Market on Aug 20, 2025お知らせ • May 13Vext Science, Inc. to Report Q1, 2025 Results on May 21, 2025Vext Science, Inc. announced that they will report Q1, 2025 results Pre-Market on May 21, 2025お知らせ • Mar 20Vext Science, Inc. to Report Q4, 2024 Results on Mar 31, 2025Vext Science, Inc. announced that they will report Q4, 2024 results at 9:30 AM, US Eastern Standard Time on Mar 31, 2025すべての更新を表示Recent updatesお知らせ • May 15Vext Science, Inc. to Report Q1, 2026 Results on May 21, 2026Vext Science, Inc. announced that they will report Q1, 2026 results Pre-Market on May 21, 2026お知らせ • Mar 31Vext Science, Inc. to Report Q4, 2025 Results on Apr 23, 2026Vext Science, Inc. announced that they will report Q4, 2025 results at 9:30 AM, US Eastern Standard Time on Apr 23, 2026お知らせ • Nov 11Vext Science, Inc. to Report Q3, 2025 Results on Nov 20, 2025Vext Science, Inc. announced that they will report Q3, 2025 results Pre-Market on Nov 20, 2025お知らせ • Oct 13Vext Science, Inc., Annual General Meeting, Dec 11, 2025Vext Science, Inc., Annual General Meeting, Dec 11, 2025.お知らせ • Aug 11Vext Science, Inc. to Report Q2, 2025 Results on Aug 20, 2025Vext Science, Inc. announced that they will report Q2, 2025 results Pre-Market on Aug 20, 2025お知らせ • May 13Vext Science, Inc. to Report Q1, 2025 Results on May 21, 2025Vext Science, Inc. announced that they will report Q1, 2025 results Pre-Market on May 21, 2025お知らせ • Apr 01Vext Science, Inc. (CNSX:VEXT) acquired the remaining 50% stake in Vapen Kentucky, LLC from Emerald Point Hemp, LLC.Vext Science, Inc. (CNSX:VEXT) acquired the remaining 50% stake in Vapen Kentucky, LLC from Emerald Point Hemp, LLC on March 26, 2025. Vext Science utilize a non-cash consideration in the transaction. For the period end date December 31, 2024, Vapen Kentucky, LLC reported $46.3 million revenue and $3.3 million net assets based on the equity accounted investment of Vext Science. Vext Science, Inc. (CNSX:VEXT) completed the acquisition of the remaining 50% stake in Vapen Kentucky, LLC from Emerald Point Hemp, LLC on March 26, 2025.お知らせ • Mar 20Vext Science, Inc. to Report Q4, 2024 Results on Mar 31, 2025Vext Science, Inc. announced that they will report Q4, 2024 results at 9:30 AM, US Eastern Standard Time on Mar 31, 2025お知らせ • Nov 07Vext Science, Inc. to Report Q3, 2024 Results on Nov 21, 2024Vext Science, Inc. announced that they will report Q3, 2024 results Pre-Market on Nov 21, 2024お知らせ • Oct 15Vext Science, Inc., Annual General Meeting, Dec 13, 2024Vext Science, Inc., Annual General Meeting, Dec 13, 2024.お知らせ • Aug 09Vext Science, Inc. to Report Q2, 2024 Results on Aug 20, 2024Vext Science, Inc. announced that they will report Q2, 2024 results at 9:30 AM, US Eastern Standard Time on Aug 20, 2024お知らせ • May 26Vext Science, Inc. to Report Q1, 2024 Results on May 29, 2024Vext Science, Inc. announced that they will report Q1, 2024 results Pre-Market on May 29, 2024お知らせ • Apr 16Vext Science, Inc. to Report Q4, 2023 Results on Apr 25, 2024Vext Science, Inc. announced that they will report Q4, 2023 results at 9:30 AM, US Eastern Standard Time on Apr 25, 2024お知らせ • Jan 17Vext Science, Inc. Announces Transition of Jason Thai Nguyen Out of Executive RoleVext Science, Inc. announced that Jason Thai Nguyen has transitioned out of his executive positions with the Company, including resigning from all positions with the Company's subsidiaries and affiliates. Mr. Nguyen will continue to serve the Company through his position as a director of the Company and Chairman of the board of directors.お知らせ • Nov 22Vext Science, Inc. to Report Q3, 2023 Results on Nov 28, 2023Vext Science, Inc. announced that they will report Q3, 2023 results Pre-Market on Nov 28, 2023お知らせ • Oct 14Vext Science, Inc., Annual General Meeting, Dec 15, 2023Vext Science, Inc., Annual General Meeting, Dec 15, 2023.お知らせ • Oct 13Vext Science, Inc. announced that it has received $11.5 million in funding from LLF Financial S.A.On October 12, 2023, Vext Science, Inc. closed the transaction. The company has now issued 67,647,058 common shares at a price of $0.17 per share for the gross proceeds of $11,500,000. In connection with the offering, the company has paid a cash finder's fee to certain registered dealers consisting of approximately $3,285. The transaction included participation from Mark Opzoomer, Trevor Smith and Sopica Special Opportunities Fund Limited managed by LLF Financial S.A. for 42,798,529 shares. Sopica Special Opportunities Fund Limited purchased 41,176,470 subordinate voting shares for $7,000,000 and its stake is increased by 21.56% (from 13.00% to 34.56%) on a non-diluted basis. Immediately prior to the Private Placement, the Acquirors beneficially owned or otherwise exercised control or direction over 10,726,849 Subordinate Voting Shares, 4,303,182 warrants to purchase Subordinate Voting Shares and 112,486 Class A common shares, representing approximately 26.79% of the issued and outstanding Subordinate Voting Shares. As a result of the Private Placement, the Acquirors beneficially own or otherwise exercise control or direction over 51,903,319 Subordinate Voting Shares, 4,303,182 Warrants and 112,486 Multiple Voting Shares, representing approximately 40.70% of the issued and outstanding Subordinate Voting Shares as at October 12, 2023.お知らせ • Aug 18Vext Science, Inc. to Report Q2, 2023 Results on Aug 23, 2023Vext Science, Inc. announced that they will report Q2, 2023 results Pre-Market on Aug 23, 2023お知らせ • Aug 11+ 1 more updateVext Science, Inc. Resigns Stephan Bankosz as Corporate Secretary, Effective August 25, 2023Vext Science, Inc. reported that Stephan Bankosz has resigned as CFO and Corporate Secretary of the Company effective August 25, 2023 to pursue other opportunities. Vext will appoint experienced financial executive and operator Trevor Smith as CFO. In the coming weeks Mr. Bankosz will assist with the transition of duties to Mr. Smith, which is expected to be completed after Vext has reported its second quarter 2023 earnings. Nalee Pham, the Company's Chief of Staff and a director of the Company's wholly-owned operating subsidiary Herbal Wellness Center, LLC has been appointed Corporate Secretary.お知らせ • May 16Vext Science, Inc. to Report Q1, 2023 Results on May 25, 2023Vext Science, Inc. announced that they will report Q1, 2023 results Pre-Market on May 25, 2023収支内訳Vext Science の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:VEXT.F 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Mar 2652-1616031 Dec 2551-1815030 Sep 2548-1711030 Jun 2544-1711031 Mar 2539-1911031 Dec 2436-2211030 Sep 2434-816030 Jun 2433-716031 Mar 2434-214031 Dec 2335414030 Sep 233558030 Jun 233478031 Mar 2334910031 Dec 22351110030 Sep 223769030 Jun 223867031 Mar 223967031 Dec 213756030 Sep 213456030 Jun 213356031 Mar 213045031 Dec 202525030 Sep 202206030 Jun 202006031 Mar 202006031 Dec 192235030 Sep 192344030 Jun 192354031 Mar 192143031 Dec 181843031 Dec 1715420質の高い収益: VEXT.Fは現在利益が出ていません。利益率の向上: VEXT.Fは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: VEXT.Fは利益が出ておらず、過去 5 年間で損失は年間63.5%の割合で増加しています。成長の加速: VEXT.Fの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: VEXT.Fは利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( -5% ) と比較することは困難です。株主資本利益率高いROE: VEXT.Fは現在利益が出ていないため、自己資本利益率 ( -28.54% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 07:09終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Vext Science, Inc. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7 アナリスト機関Matt BottomleyCanaccord GenuityShaan MirCanaccord GenuityNeal GilmerHaywood Securities Inc.4 その他のアナリストを表示
お知らせ • May 15Vext Science, Inc. to Report Q1, 2026 Results on May 21, 2026Vext Science, Inc. announced that they will report Q1, 2026 results Pre-Market on May 21, 2026
お知らせ • Mar 31Vext Science, Inc. to Report Q4, 2025 Results on Apr 23, 2026Vext Science, Inc. announced that they will report Q4, 2025 results at 9:30 AM, US Eastern Standard Time on Apr 23, 2026
お知らせ • Nov 11Vext Science, Inc. to Report Q3, 2025 Results on Nov 20, 2025Vext Science, Inc. announced that they will report Q3, 2025 results Pre-Market on Nov 20, 2025
お知らせ • Aug 11Vext Science, Inc. to Report Q2, 2025 Results on Aug 20, 2025Vext Science, Inc. announced that they will report Q2, 2025 results Pre-Market on Aug 20, 2025
お知らせ • May 13Vext Science, Inc. to Report Q1, 2025 Results on May 21, 2025Vext Science, Inc. announced that they will report Q1, 2025 results Pre-Market on May 21, 2025
お知らせ • Mar 20Vext Science, Inc. to Report Q4, 2024 Results on Mar 31, 2025Vext Science, Inc. announced that they will report Q4, 2024 results at 9:30 AM, US Eastern Standard Time on Mar 31, 2025
お知らせ • May 15Vext Science, Inc. to Report Q1, 2026 Results on May 21, 2026Vext Science, Inc. announced that they will report Q1, 2026 results Pre-Market on May 21, 2026
お知らせ • Mar 31Vext Science, Inc. to Report Q4, 2025 Results on Apr 23, 2026Vext Science, Inc. announced that they will report Q4, 2025 results at 9:30 AM, US Eastern Standard Time on Apr 23, 2026
お知らせ • Nov 11Vext Science, Inc. to Report Q3, 2025 Results on Nov 20, 2025Vext Science, Inc. announced that they will report Q3, 2025 results Pre-Market on Nov 20, 2025
お知らせ • Oct 13Vext Science, Inc., Annual General Meeting, Dec 11, 2025Vext Science, Inc., Annual General Meeting, Dec 11, 2025.
お知らせ • Aug 11Vext Science, Inc. to Report Q2, 2025 Results on Aug 20, 2025Vext Science, Inc. announced that they will report Q2, 2025 results Pre-Market on Aug 20, 2025
お知らせ • May 13Vext Science, Inc. to Report Q1, 2025 Results on May 21, 2025Vext Science, Inc. announced that they will report Q1, 2025 results Pre-Market on May 21, 2025
お知らせ • Apr 01Vext Science, Inc. (CNSX:VEXT) acquired the remaining 50% stake in Vapen Kentucky, LLC from Emerald Point Hemp, LLC.Vext Science, Inc. (CNSX:VEXT) acquired the remaining 50% stake in Vapen Kentucky, LLC from Emerald Point Hemp, LLC on March 26, 2025. Vext Science utilize a non-cash consideration in the transaction. For the period end date December 31, 2024, Vapen Kentucky, LLC reported $46.3 million revenue and $3.3 million net assets based on the equity accounted investment of Vext Science. Vext Science, Inc. (CNSX:VEXT) completed the acquisition of the remaining 50% stake in Vapen Kentucky, LLC from Emerald Point Hemp, LLC on March 26, 2025.
お知らせ • Mar 20Vext Science, Inc. to Report Q4, 2024 Results on Mar 31, 2025Vext Science, Inc. announced that they will report Q4, 2024 results at 9:30 AM, US Eastern Standard Time on Mar 31, 2025
お知らせ • Nov 07Vext Science, Inc. to Report Q3, 2024 Results on Nov 21, 2024Vext Science, Inc. announced that they will report Q3, 2024 results Pre-Market on Nov 21, 2024
お知らせ • Oct 15Vext Science, Inc., Annual General Meeting, Dec 13, 2024Vext Science, Inc., Annual General Meeting, Dec 13, 2024.
お知らせ • Aug 09Vext Science, Inc. to Report Q2, 2024 Results on Aug 20, 2024Vext Science, Inc. announced that they will report Q2, 2024 results at 9:30 AM, US Eastern Standard Time on Aug 20, 2024
お知らせ • May 26Vext Science, Inc. to Report Q1, 2024 Results on May 29, 2024Vext Science, Inc. announced that they will report Q1, 2024 results Pre-Market on May 29, 2024
お知らせ • Apr 16Vext Science, Inc. to Report Q4, 2023 Results on Apr 25, 2024Vext Science, Inc. announced that they will report Q4, 2023 results at 9:30 AM, US Eastern Standard Time on Apr 25, 2024
お知らせ • Jan 17Vext Science, Inc. Announces Transition of Jason Thai Nguyen Out of Executive RoleVext Science, Inc. announced that Jason Thai Nguyen has transitioned out of his executive positions with the Company, including resigning from all positions with the Company's subsidiaries and affiliates. Mr. Nguyen will continue to serve the Company through his position as a director of the Company and Chairman of the board of directors.
お知らせ • Nov 22Vext Science, Inc. to Report Q3, 2023 Results on Nov 28, 2023Vext Science, Inc. announced that they will report Q3, 2023 results Pre-Market on Nov 28, 2023
お知らせ • Oct 14Vext Science, Inc., Annual General Meeting, Dec 15, 2023Vext Science, Inc., Annual General Meeting, Dec 15, 2023.
お知らせ • Oct 13Vext Science, Inc. announced that it has received $11.5 million in funding from LLF Financial S.A.On October 12, 2023, Vext Science, Inc. closed the transaction. The company has now issued 67,647,058 common shares at a price of $0.17 per share for the gross proceeds of $11,500,000. In connection with the offering, the company has paid a cash finder's fee to certain registered dealers consisting of approximately $3,285. The transaction included participation from Mark Opzoomer, Trevor Smith and Sopica Special Opportunities Fund Limited managed by LLF Financial S.A. for 42,798,529 shares. Sopica Special Opportunities Fund Limited purchased 41,176,470 subordinate voting shares for $7,000,000 and its stake is increased by 21.56% (from 13.00% to 34.56%) on a non-diluted basis. Immediately prior to the Private Placement, the Acquirors beneficially owned or otherwise exercised control or direction over 10,726,849 Subordinate Voting Shares, 4,303,182 warrants to purchase Subordinate Voting Shares and 112,486 Class A common shares, representing approximately 26.79% of the issued and outstanding Subordinate Voting Shares. As a result of the Private Placement, the Acquirors beneficially own or otherwise exercise control or direction over 51,903,319 Subordinate Voting Shares, 4,303,182 Warrants and 112,486 Multiple Voting Shares, representing approximately 40.70% of the issued and outstanding Subordinate Voting Shares as at October 12, 2023.
お知らせ • Aug 18Vext Science, Inc. to Report Q2, 2023 Results on Aug 23, 2023Vext Science, Inc. announced that they will report Q2, 2023 results Pre-Market on Aug 23, 2023
お知らせ • Aug 11+ 1 more updateVext Science, Inc. Resigns Stephan Bankosz as Corporate Secretary, Effective August 25, 2023Vext Science, Inc. reported that Stephan Bankosz has resigned as CFO and Corporate Secretary of the Company effective August 25, 2023 to pursue other opportunities. Vext will appoint experienced financial executive and operator Trevor Smith as CFO. In the coming weeks Mr. Bankosz will assist with the transition of duties to Mr. Smith, which is expected to be completed after Vext has reported its second quarter 2023 earnings. Nalee Pham, the Company's Chief of Staff and a director of the Company's wholly-owned operating subsidiary Herbal Wellness Center, LLC has been appointed Corporate Secretary.
お知らせ • May 16Vext Science, Inc. to Report Q1, 2023 Results on May 25, 2023Vext Science, Inc. announced that they will report Q1, 2023 results Pre-Market on May 25, 2023